Treatment of Candidiasis

Oropharyngeal Candidiasis

For initial episodes of oropharyngeal candidiasis, oral fluconazole 100 mg daily for 7-14 days is as effective as—and in some studies superior to—topical agents like clotrimazole troches or nystatin, according to the Infectious Diseases Society of America 1, 2, 3, 4, 5
Symptomatic relapses occur sooner with topical therapy than with fluconazole in HIV-infected patients, making fluconazole the preferred choice for sustained disease control 1, 2, 3, 4, 5
Most patients respond initially to topical therapy, but fluconazole provides more durable responses with better prevention of recurrence 1, 2, 3, 4, 5
Both topical and systemic therapy can lead to resistance development, so the choice should not be based on resistance concerns alone 1, 2, 3
For uncomplicated initial episodes in immunocompetent patients, topical agents remain acceptable first-line options, as recommended by the Centers for Disease Control and Prevention 6, 3, 4, 5

For esophageal candidiasis, topical therapy is completely ineffective and systemic antifungal therapy is always required, according to the Infectious Diseases Society of America 1, 2, 3, 4, 5, 7
Fluconazole 200-400 mg daily for 14-21 days is the recommended first-line treatment, as suggested by the American College of Gastroenterology 3
Topical agents cannot reach the esophageal mucosa in therapeutic concentrations, making them useless for this indication 1, 2, 4, 5

Do not use topical therapy for esophageal candidiasis—it will fail, as stated by the Infectious Diseases Society of America 1, 2, 3, 4, 5, 7
Do not assume topicals are "safer" to avoid resistance—resistance develops with both topical and systemic therapy, according to the Centers for Disease Control and Prevention 1, 2, 3
For immunocompromised patients, favor fluconazole over topicals due to lower relapse rates, as recommended by the National Institutes of Health 1, 2, 3, 4, 5
Avoid using fluconazole capsules interchangeably with itraconazole capsules—itraconazole solution is better absorbed, but fluconazole remains superior to ketoconazole and itraconazole capsules, as stated by the American College of Clinical Pharmacy 1, 2, 3, 4, 5

The presentation of severe throat pain with painful swallowing in an HIV patient with oral candidiasis strongly suggests esophageal involvement 8
Systemic antifungal therapy is always required for esophageal candidiasis—topical agents cannot reach therapeutic concentrations in the esophageal mucosa and will fail 8

The Infectious Diseases Society of America recommends fluconazole 200-400 mg (3-6 mg/kg) orally daily for 14-21 days for presumed esophageal candidiasis 8, 9, 10
If the patient cannot swallow, intravenous fluconazole 400 mg (6 mg/kg) daily is recommended 8
A diagnostic trial of fluconazole is appropriate before performing endoscopy, as most patients with esophageal candidiasis will have symptom resolution within 7 days 8, 11
For oropharyngeal candidiasis alone, fluconazole 100 mg daily for at least 7 days would be sufficient 9, 10, 12

The Centers for Disease Control and Prevention recommends that antiretroviral therapy should be initiated or restarted as soon as possible, as this is the most effective long-term strategy for reducing mucosal candidiasis 8, 9, 10, 12
Effective antiretroviral therapy decreases oral Candida carriage rates and reduces symptomatic oropharyngeal candidiasis frequency 8, 13

Treatment failure is defined as persistent symptoms after 7-14 days of appropriate therapy 14, 15
For fluconazole-refractory disease, switch to itraconazole solution 200 mg daily (64-80% response rate) 8, 13, 9
Alternative options include posaconazole 400 mg twice daily, voriconazole 200 mg twice daily, or an echinocandin 8, 9, 10

The Infectious Diseases Society of America guidelines recommend switching to oral fluconazole 100-200 mg daily for 7-14 days, as it is superior to nystatin with cure rates of 84-100% compared to nystatin's 32-51% in head-to-head trials, with the highest level of evidence (AI rating) 16, 17
Oral fluconazole is the definitive next step when thrush persists after 2 months of nystatin therapy, as stated by the Infectious Diseases Society of America guidelines, which explicitly state that fluconazole is "as effective as and in some studies superior to topical therapy" for oropharyngeal candidiasis 16, 17

If fluconazole cannot be used, itraconazole solution 200 mg daily for 7-14 days is equally efficacious, according to the Infectious Diseases Society of America guidelines 16, 17
Clotrimazole troches (10 mg five times daily for 7-14 days) are another topical alternative that may work when nystatin has failed, as they are more effective than nystatin, as recommended by the Centers for Disease Control and Prevention 18

A 2-month treatment failure warrants evaluation for immunocompromised state (HIV, diabetes, corticosteroid use, chemotherapy), as recommended by the Infectious Diseases Society of America guidelines 16, 17
A 2-month treatment failure also warrants evaluation for denture-related disease requiring thorough denture disinfection, as recommended by the Infectious Diseases Society of America guidelines 16, 17
Non-albicans Candida species or azole-resistant strains should be investigated in cases of treatment failure, as recommended by the Infectious Diseases Society of America guidelines 16, 17

Second-line treatment with itraconazole solution >200 mg daily responds ~67% of the time, as recommended by the Infectious Diseases Society of America guidelines 16, 17
Third-line treatment with amphotericin B oral suspension 100 mg/mL, 1 mL four times daily, is an option for fluconazole-refractory disease, as recommended by the Infectious Diseases Society of America guidelines 16, 17

Ketoconazole or itraconazole capsules should not be used as alternatives to fluconazole, as they have variable absorption and are less effective, as stated by the Infectious Diseases Society of America guidelines 16, 17
Dentures should not be overlooked, as denture-related candidiasis requires disinfection of the prosthesis for definitive cure, as recommended by the Infectious Diseases Society of America guidelines 16, 17

For patients with frequent or disabling recurrences, chronic suppressive therapy with fluconazole may be warranted, though this should be used judiciously to minimize resistance development, as recommended by the Infectious Diseases Society of America guidelines 16, 17